# Retatrutide: Research Overview — Freebase Peptides > A literature summary of retatrutide (LY3437943), the investigational GIP/GLP-1/glucagon triple-agonist peptide: mechanism, Phase 2 efficacy in obesity and type 2 diabetes, liver-fat data, and safety signals. LY3437943 — a single molecule targeting GIP, GLP-1, and glucagon receptors simultaneously — with the largest Phase 2 weight-loss signal in the incretin class as of mid-2026. ## The short version Retatrutide (also called LY3437943) is an investigational 39-amino-acid peptide designed to activate three hormone receptors at once: GIP (glucose-dependent insulinotropic polypeptide receptor), GLP-1 (glucagon-like peptide-1 receptor), and the glucagon receptor. Adding the glucagon arm to the dual GIP/GLP-1 agonism found in other incretin-class compounds is what distinguishes it — glucagon receptor activation adds energy expenditure and lipid mobilization on top of the appetite suppression and insulin-sensitization produced by the other two [1]. In a 48-week Phase 2 trial in adults with obesity, retatrutide at 12 mg once weekly produced a mean body-weight reduction of 24.2% versus 2.1% with placebo [4]. In a parallel Phase 2 trial in type 2 diabetes, the 12 mg group achieved an HbA1c reduction of 2.02% at 24 weeks and a 16.94% body-weight reduction at 36 weeks [5]. These are trial results in supervised clinical settings — not general-use outcomes. Retatrutide is not approved by any regulator as of mid-2026. Phase 3 TRIUMPH trials are underway. This page reports the research; it is not medical advice and lists no human dose. ## What it is Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone, with a C20 fatty-diacid conjugated to enable albumin binding and extend its half-life — the same acylation strategy used to achieve once-weekly dosing. Its molecular formula in free-acid form is C221H342N46O68. The research shorthand LY3437943 (Eli Lilly's compound number) is the identifier used in trial registrations. The compound is sometimes called a GGG tri-agonist or triple-incretin-receptor agonist in the literature [2]. It is an investigational drug, not available as a prescription product outside clinical trials, and not available as an approved consumer medication. ## How it works Cryo-electron microscopy structures resolved retatrutide engaging all three receptor complexes — GLP-1R, GIPR, and GCGR — simultaneously [2]. Its relative potency at each receptor differs from native hormones: approximately 8.9-fold more potent than native GIP at GIPR, but 0.3-fold and 0.4-fold compared to native glucagon and native GLP-1 at GCGR and GLP-1R respectively. This asymmetry is deliberate — strong GIP agonism enhances glucose-dependent insulin secretion and likely tolerability, while partial glucagon agonism adds metabolic throughput without an unacceptable cardiovascular or glycemic burden [2]. In plain terms: the GLP-1 and GIP arms suppress appetite and improve postprandial glucose handling. The glucagon arm adds thermogenic energy expenditure and drives lipid mobilization — the mechanism believed to underlie retatrutide's larger weight-loss magnitude compared to dual or single agonists. Metabolomics and lipidomics from Phase 2 participants confirmed dose-dependent reductions in triglycerides and insulin-resistance biomarkers, with fatty-acid-oxidation-cluster changes mediating 23.2% of the weight-reduction response in non-T2D participants [7]. ## What the research shows *Phase 2 obesity (48 weeks).* In 338 adults with obesity, once-weekly retatrutide at 12 mg produced a mean body-weight change of -24.2% versus -2.1% with placebo at 48 weeks. GI adverse events were dose-related and mostly mild-to-moderate; a dose-dependent heart-rate increase peaked around 24 weeks [4]. *Phase 2 type 2 diabetes (36 weeks).* In 281 adults with T2D, retatrutide 12 mg reduced HbA1c by 2.02% at 24 weeks and body weight by 16.94% at 36 weeks versus placebo (-0.01% and -3.00% respectively). Mild-moderate GI events in 35%; no severe hypoglycemia and no deaths [5]. *Liver fat (MASLD substudy, 24/48 weeks).* In 98 participants with obesity/overweight and metabolic-dysfunction-associated steatotic liver disease (MASLD, no T2D), retatrutide 12 mg reduced liver fat by a relative 82.4% at 24 weeks; 86% of participants at that dose reached normal liver-fat levels (<5% by MRI-PDFF). Reductions were sustained to 48 weeks (-86.0% at 12 mg) [3]. *Phase 1b (12 weeks, T2D).* The first-in-human multiple-dose study in 72 adults with T2D established an approximate 6-day half-life supporting once-weekly dosing. Placebo-adjusted weight loss at the highest dose reached -8.96 kg over 12 weeks [6]. *Structure.* Cryo-EM structures showed retatrutide engaging all three receptor complexes with distinct ECL1 conformations at each — a structural basis for its tri-agonism [2]. *Metabolomics.* Post-hoc analysis of two Phase 2 RCTs found dose-dependent reductions in triglycerides enriched in short-chain/saturated acyl chains and improvements in insulin-resistance biomarkers (branched-chain amino acids, 2-hydroxybutyrate, urate), in a direction associated with reduced cardiovascular risk [7]. ## Reported effects, cautions & safety The following community-reported experiences come from peptide research communities and are **anecdotal, not clinical evidence** — no verified doses, no clinical oversight. *Frequently reported in community accounts:* Strong appetite suppression (community members describe near-complete silencing of intrusive food thoughts — what they call "food noise going quiet"). Rapid and pronounced weight reduction, qualitatively faster than other GLP-1-class experiences. Nausea during initial weeks and dose escalation, peaking 4-8 hours post-injection, diminishing with time. *Commonly reported:* Elevated resting heart rate, particularly in the hours after administration, tracking with the dose-dependent increases documented in Phase 2 trials. Increased body warmth or mild thermogenic sensation, attributed in community discussion to glucagon-receptor-mediated thermogenesis. Sulfur burps, constipation, and early fatigue or low energy — all consistent with GI motility slowing and aggressive caloric restriction. *Occasionally reported:* Sleep disturbances in the initial weeks. Mood uplift and reduced anxiety around food. Lean-mass concern with rapid weight loss. Cited safety cautions from the clinical literature: - *Unapproved compound, unverified supply.* Retatrutide remains investigational; material sold through gray-market research channels cannot be confirmed as authentic retatrutide at stated concentration. The FDA issued over 50 warning letters to retatrutide vendors in 2025 [4]. - *GI adverse events.* Nausea affected up to 45% of participants at the highest dose in Phase 2 and was the principal driver of the 18% discontinuation rate at that dose level [4]. - *Heart-rate increase.* Mean resting heart rate rose approximately 5-7 bpm at highest doses, peaking around 24 weeks; individuals with pre-existing arrhythmias or cardiovascular disease face unmonitored risk [4][1]. - *Hypoglycemia with insulin or sulfonylureas.* Combined GLP-1/GIP agonism can drive blood glucose below safe thresholds in the context of exogenous insulin or sulfonylurea medications [5][6]. - *Lean-mass loss.* A body-composition substudy confirmed reductions in lean body mass alongside fat mass; adequate protein intake and resistance training are widely discussed as protective [4]. - *Long-term unknowns.* All pivotal outcome trials are ongoing; cardiovascular, renal, and long-term durability data do not yet exist [1]. ![Retatrutide triple-receptor agonist abstract metabolic illustration](/images/retatrutide.webp) ## Where it fits in metabolic research Among the three compounds on this desk, retatrutide is the lead and the most data-rich — but all existing data come from Phase 2 trials in supervised settings. Its triple-receptor mechanism distinguishes it structurally from any approved incretin therapy, and the Phase 2 weight-loss magnitude is the largest reported for any pharmacological agent to date. Phase 3 TRIUMPH trials are ongoing, meaning the pivotal evidence is still accumulating. Read alongside [MOTS-c](/mots-c), which works through the entirely different AMPK/mitochondrial axis, and [tesamorelin](/tesamorelin), the desk's only approved compound, retatrutide illustrates the leading edge of incretin pharmacology before regulatory completion. See the [comparison page](/compare) for how it lines up against the others. --- A clinical briefing on metabolic research peptides — peer-reviewed citations, stated approval status, no doses and no products.